IN.PACT™ AV Access Post-Approval Study (PAS002)
← catalyst calendarSponsored by Medtronic (industry) · MDT — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
240actual
Sites
20
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-11-13 | actual | When the study began enrolling |
| Primary completion | 2025-06-03 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2020-09-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Arteriovenous Fistula
- Arteriovenous Fistula Stenosis
- Arteriovenous Fistula Occlusion
- Fistula
Interventions
- Combination product: IN.PACT™ AV Drug Coated Balloon (DCB) - Primary Cohort
- Combination product: IN.PACT™ AV Drug Coated Balloon (DCB) - Extended Cohort
Primary outcome
what the primary-completion date above is the date OFInfection and Infestations Serious Adverse Events
measured Through 12 months post-index procedure
Permalink · MDT's whole pipeline · Catalyst calendar · Every registered study · What changed